Abstract:Lung cancer is the most prevalent malignant tumor and the primary cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of all lung cancer cases. [ 1–3 ] NSCLC is the most common histological type and has a poor prognosis. Stage IV NSCLC is associated with a 5-year survival rate of ~1%. [ 4 ] The discovery of driver mutations has drastically changed clinical practice in patients with lung tumors. Multiplexed testing contributes to physicians' selection of therapies; individuals with drivers receiving a matched targeted agent live longer at the same time. [ 5 ] Osimertinib is a third-generation irreversible oral epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and epidermal growth factor receptor (EGFR) T790M resistance mutations. [ 6 , 7 ] The previous trials have shown that osimertinib is associated with significantly improved efficacy and a favorable safety profile in patients with EGFR mutation-positive, locally advanced, or metastatic NSCLC, both as a first-line treatment and as a second-line treatment for progression after first-line EGFR-TKI treatment. [ 8 , 9 ] Moreover, EGFR T790M mutation-positive advanced NSCLC patients with poor performance status could benefit from osimertinib therapy. [ 10 ] However, in addition to providing an excellent survival benefit, tyrosine kinase inhibitors (TKIs) can also induce adverse events, which is a major management challenge for patients with advanced NSCLC. TKI-related adverse events such as diarrhea, paronychia, rash, decreased platelet count, decreased appetite, interstitial lung disease (ILD), and pneumothorax are commonly reported. [ 11–13 ] Drug-related lung damage, including drug-related pneumonia, pneumothorax, and diffuse alveolar hemorrhage, is a particularly worrisome adverse event. Herein, we report a case of lung adenocarcinoma with multiple metastases that developed severe bilateral spontaneous pneumothorax when treated with osimertinib as first-line treatment and died of multiple organ failure.

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

Hemorrhage of Brain Metastasis from Non-Small Cell Lung Cancer Post Gefitinib Therapy: Two Case Reports and Review of the Literature

Tumoral hemorrhage of brain metastasis from non-small cell lung cancer after gefitinib therapy : two case reports and literature review

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report

Quick Regression of Brain Metastases from Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Case Report and Literature Review.

Small Bowel Perforation Secondary to Metastatic Lung Cancer with Emphasis on the Administration of Erlotinib: a Case Report

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review

EGFR-tyrosine Kinase Inhibitor Treatment in a Patient with Advanced Non-Small Cell Lung Cancer and Concurrent Exon 19 and 21 EGFR Mutations: A Case Report and Review of the Literature.

Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells

Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib

Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report

Transformation to Small Cell Lung Cancer and Activation of KRAS During Long-Term Erlotinib Maintenance in a Patient with Non-Small Cell Lung Cancer: A Case Report

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib

P3.05-016 Mitochondial Pathway Mediated Apoptosis is Involved in Erlotinib-Induced Cytoxicity in Hepatic Cells

Osimertinib-induced severe bilateral pneumothorax: A case report

EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report